Selvita S.A. (WSE:SLV) signed an agreement to acquire 100% stake in Fidelta D.O.O. from Galapagos NV (ENXTAM:GLPG) for an enterprise value of €31.2 million on November 23, 2020. The acquisition substantially expands Selvita's integrated drug discovery services offering. Fidelta to continue performing drug discovery services for Galapagos for the next five years.

The transaction will almost double Selvita's revenues. Selvita S.A. signs loan deals with PKO BP for up to €21.8 million total for financing the 100% acquisition of Fidelta d.o.o. The transaction is subject to customary closing conditions and is expected to close on the January 4, 2021. Upon completion of the acquisition, Fidelta will be fully consolidated under the Selvita Group, and will continue to operate under the Fidelta name.